Herpes vaccine to be tested in humans after best result yet in animals

Hopes for a genital herpes vaccine have been raised by a trial treatment that stops genital lesions and low-lying infections in guinea pigs and mice
Source: New Scientist - Health - Category: Consumer Health News Source Type: research

Related Links:

Herpes simplex virus-2 (HSV-2) is a leading cause of sexually transmitted infections for which no effective vaccines or prophylactic treatment currently exist. Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor involved in the detoxification of reactive oxygen species (ROS) and has been more recently shown to regulate inflammatory and antiviral responses. Here, we evaluated the importance of Nrf2 in the control of HSV-2 genital infection and its role in the regulation of HSV-induced innate antiviral immunity. Comparison of antiviral gene expression profile by RNA-sequencing analysis of wild type a...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
THURSDAY, Aug. 1, 2019 -- It's only been tried so far in guinea pigs, but researchers say a combination of a vaccine and a medicated cream could greatly lower recurrence of genital herpes. The condition is very common, affecting about one out of...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
Eduardo I. Tognarelli1, Tomás F. Palomino1, Nicolás Corrales1, Susan M. Bueno1, Alexis M. Kalergis1,2 and Pablo A. González1* 1Millennium Institute on Immunology and Immunotherapy, Departamento de Genética Molecular y Microbiología, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile 2Departamento de Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) have co-evolved with humans for thousands o...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
In this study we have evaluated whether our OMVs vaccine is capable of overcoming the deficiencies of commercial vaccines in both controlling infections caused by PRN(-) isolate/strain and inducing memory immunity. We found that our OMVs-based formulation has a higher protective capacity against the PRN(-) bacteria than that induced with a commercial aP vaccine. We found that CD4 T cells with a tissue-resident memory (TRM) cell phenotype (CD44+CD62LlowCD69+ and/or CD103+) accumulated in the lungs of mice after the second OMVs vaccine immunization. CD4 TRM cells were also detected in mice immunized with wP vaccine, but not ...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Reena Goswami1, Gayatri Subramanian2, Liliya Silayeva1, Isabelle Newkirk1, Deborah Doctor1, Karan Chawla2, Saurabh Chattopadhyay2, Dhyan Chandra3, Nageswararao Chilukuri1 and Venkaiah Betapudi1,4* 1Neuroscience Branch, Research Division, United States Army Medical Research Institute of Chemical Defense, Aberdeen, MD, United States 2Department of Medical Microbiology and Immunology, University of Toledo College of Medicine and Life Sciences, Toledo, OH, United States 3Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States 4Department of Physiology and Biophysics, Case Western Reserve University, Clev...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Christine I. Alston1,2 and Richard D. Dix1,2* 1Department of Biology, Viral Immunology Center, Georgia State University, Atlanta, GA, United States 2Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA, United States Suppressor of cytokine signaling (SOCS) proteins provide selective negative feedback to prevent pathogeneses caused by overstimulation of the immune system. Of the eight known SOCS proteins, SOCS1 and SOCS3 are the best studied, and systemic deletion of either gene causes early lethality in mice. Many viruses, including herpesviruses such as herpes simplex virus and cytomega...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Conclusions Apart West Nile virus (78), thousands of congenital microcephaly cases, fetal brain tissue damage and neurological syndromes have been associated with ZIKV infection. Unfortunately, the epidemics of this mosquito born, and a relative stable virus is on a rise. Although congenital microcephaly is a rare disorder however, due to lack of standardized diagnostic test facilities, the incidence in the geographically widespread ZIKV epidemic regions is higher. Animals studies showed that ZIKV is a neurotropic virus. It directly targets the developing embryonic brain cells by inducing apoptosis, cell-cycle arrest, and...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Conclusions: These finding suggest that Poly-ICLC could be safely used for inducing transient innate immune responses in treated HIV+ subjects indicating promise as an adjuvant for HIV therapeutic vaccines. Trial Registration: www.ClinicalTrials.gov, identifier: NCT02071095. Introduction Innate immune dysregulation during HIV infection hinders the formation of anti-HIV adaptive immunity (1–6) resulting in rampant viral dissemination and progression to AIDS. Adherence to combination anti-retroviral therapy (cART) regimens controls viremia, restores CD4+T cell counts and reverses immune dysfunction to a larg ext...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Publication date: Available online 27 December 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Mathis Kopp, Ulrich Wilhelm Aufderhorst, Mira Alt, Ulf Dittmer, Anna-Maria Eis-Hübinger, Bernd Giebel, Michael Roggendorf, Matthias Epple, Adalbert KrawczykAbstractHerpes simplex viruses 1 and 2 are among the most ubiquitous human infections and persist lifelong in their host. Upon primary infection or reactivation from ganglia, the viruses spread by direct cell–cell contacts (cell-to-cell spread) and thus escape from the host immune response. We have developed a monoclonal antibody (mAb 2c), w...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - Category: Nanotechnology Source Type: research
Universities in Louisiana and Pennsylvania have developed vaccines that stop monkeys and guinea pigs developing symptoms after being exposed to aggressive forms of the genital herpes virus.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Genital Herpes | Guinea Health | Health | Herpes | Vaccines | Veterinary Vaccinations